KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Market Cap	91.46B
Revenue (ttm)	121.55B
Net Income (ttm)	3.85B
Shares Out	57.45M
EPS (ttm)	66.96
PE Ratio	23.77
Forward PE	21.94
Dividend	52.00 (3.26%)
Ex-Dividend Date	Mar 28, 2025

Volume	105,400
Average Volume	226,580
Open	1,597.00
Previous Close	1,596.00
Day's Range	1,591.00 - 1,610.00
52-Week Range	1,331.00 - 1,880.00
Beta	-0.05
RSI	63.77
Earnings Date	May 12, 2025

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis th...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1923
• Employees: 2,042
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4569

Financial Performance

In 2023, KYORIN Pharmaceutical's revenue was 119.53 billion, an increase of 5.53% compared to the previous year's 113.27 billion. Earnings were 5.32 billion, an increase of 12.68%.